No Data
Shenzhen Mindray Bio-Medical Electronics (300760.SZ): Continuous strengthening of business matrix through mergers and acquisitions, achieving industry-leading growth.
Against the backdrop of the continuous growth in global demand for medical instruments, an undeniable phenomenon is that medical instrument companies, especially leading ones, are utilizing external expansion mergers to quickly seize market opportunities and further enhance performance. Drawing from the growth path of global medical instrument giants that span hundreds of years, it can be seen that mergers and acquisitions are a necessary path for enterprises to achieve rapid growth and industry leadership. According to incomplete statistics from public data, as of 2024, foreign-funded medical instrument companies have completed 12 mergers and acquisitions, with a total amount reaching approximately 168.59 billion Chinese yuan, covering cardiovascular intervention, stroke pre
Earnings Miss: Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Missed EPS By 13% And Analysts Are Revising Their Forecasts
Mindray Healthcare: Third Quarter 2024 Report
Delayed hospital purchases, sluggish non-rigid medical demand, and other factors dragged down shenzhen mindray bio-medical electronics' Q3 net income by 9.31% | Financial report watch
Due to factors such as delayed hospital procurement, tight hospital construction funds, and sluggish non-rigid medical demand, in the third quarter, Shenzhen Mindray Bio-Medical Electronics' net income decreased by 9.31% year-on-year, while total revenue increased by 1.43% year-on-year. In the second interim profit distribution in 2024, Shenzhen Mindray Bio-Medical Electronics will distribute 16.50 yuan for every 10 shares.
Express News | Mindray Bio-Medical Electronics Q3 Net Profit Down 9.3% Y/Y
Is There An Opportunity With Shenzhen Mindray Bio-Medical Electronics Co., Ltd.'s (SZSE:300760) 27% Undervaluation?
No Data
No Data
102884128 : getting disappointed with this counter. every day drop.